Patents Examined by Evelyn Mei Huang
-
Patent number: 7078523Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: October 7, 2003Date of Patent: July 18, 2006Assignee: 3M Innovative Properties CompanyInventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
-
Patent number: 7074806Abstract: A compound of Formula (IA) or Formula (IB) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, or a tautomer prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.Type: GrantFiled: May 28, 2003Date of Patent: July 11, 2006Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Thomas Martin Kirrane, Jr., Daniel Kuzmich, John Robert Proudfoot, Hossein Razavi, David Thomson
-
Patent number: 7049439Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: October 7, 2003Date of Patent: May 23, 2006Assignee: 3M Innovative Properties Co.Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
-
Patent number: 7041675Abstract: The invention relates to compounds of the formula I and the tautomeric forms, possible enantiomeric and diasteromeric forms thereof, and prodrugs thereof, and use thereof as PARP inhibitors.Type: GrantFiled: January 25, 2001Date of Patent: May 9, 2006Assignee: Abbott GmbH & Co. KGInventors: Wilfried Lubisch, Michael Kock, Thomas Hoeger, Roland Grandel, Reinhold Mueller, Sabine Schult
-
Patent number: 7037919Abstract: Tetrahydroquinoline derivatives of general formula (I) or salts thereof, having a specific and strong binding affinity for AR and exhibiting AR agonism or antagonism; and pharmaceutical compositions containing the derivatives or the salts.Type: GrantFiled: October 6, 2000Date of Patent: May 2, 2006Assignee: Kaken Pharmaceutical Co. Ltd.Inventors: Keigo Hanada, Kazuyuki Furuya, Kiyoshi Inoguchi, Motonori Miyakawa, Naoya Nagata
-
Patent number: 7030128Abstract: A class of imidazo[1,2-?]pyrimidine derivatives, substituted at the 3-position by an optionally substituted five-membered or six-membered heteroaromatic ring, are selective ligands for GABAA receptors, in particular having good affinity for the ?2 and/or ?3 and/or ?5 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.Type: GrantFiled: March 19, 2002Date of Patent: April 18, 2006Assignee: Merck Sharp & Dohme Ltd.Inventors: Wesley Peter Blackaby, Jose Luis Castro Pineiro, Mark Stuart Chambers, Simon Charles Goodacre, David James Hallett, Philip Jones, Richard Thomas Lewis, Angus Murray MacLeod, Robert James Maxey, Kevin William Moore, Leslie Joseph Street
-
Patent number: 7012080Abstract: This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 represents a hydrogen atom or a halogen atom; R2 represents a methyl group or an ethyl group; R3 represents a branched alkyl group having from 3 to 6 carbon atoms or an alkyl group having from 3 to 6 carbon atoms substituted by an alkoxy group having from 1 to 6 carbon atoms; with the proviso that when the terminal carbon atom of said alkyl group of R3 is substituted by said alkoxy group, said alkyl group is a branched alkyl group. These compounds have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.Type: GrantFiled: September 17, 2003Date of Patent: March 14, 2006Assignee: Pfizer Inc.Inventors: Satoru Iguchi, Yasuhiro Katsu, Kana Kon-I, Hirohide Noguchi, Chikara Uchida
-
Patent number: 7001900Abstract: The invention provides compounds of Formula I: wherein Azabicyclo is W is a six-membered heterocyclic ring system having 1–2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six-six-fused-ring system, and further having 1–2 substitutents independently selected from R3. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat diseases or conditions in which ?7 is known to be involved.Type: GrantFiled: February 14, 2003Date of Patent: February 21, 2006Assignee: Pfizer Inc.Inventors: Eric Jon Jacobsen, Jason K. Myers, Daniel Patrick Walker, Donn G. Wishka, Steven Charles Reitz, David W. Piotrowski, Brad A. Acker, Vincent E. Groppi, Jr.
-
Patent number: 6992086Abstract: The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.Type: GrantFiled: November 17, 2003Date of Patent: January 31, 2006Assignee: Telik, Inc.Inventors: Edgardo Laborde, Louise Robinson, Fanying Meng, Brian T. Peterson, Hugo O. Villar, Steven E. Anuskiewicz, Yoshiro Ishiwata, Shoji Yokochi, Yukiharu Matsumoto, Takuji Kakigami, Hideaki Inagaki, Takahito Jomori, Kouji Matsushima
-
Patent number: 6992095Abstract: The invention relates to novel stilbene compounds having the general formula (I): as well as to pharmaceutical compositions for use in human or veterinary medicine, including dermatological, rheumatic, respiratory, cardiovascular and ophthalmic conditions and cosmetic compositions and methods of use thereof.Type: GrantFiled: October 2, 2003Date of Patent: January 31, 2006Assignee: Galderma Research & Development, S.N.C.Inventors: Jean-Michel Bernardon, Bruno Charpentier
-
Patent number: 6989389Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: October 29, 2003Date of Patent: January 24, 2006Assignee: 3M Innovative Properties Co.Inventors: Philip D. Heppner, Leslie J. Charles, Joseph F. Dellaria, Bryon A. Merrill, John W. Mickelson
-
Patent number: 6989390Abstract: Disclosed is a salt of amonafide or amonafide analogs represented Structural Formula (I): R1 is —(CH2)nN+HR3R4 X? or R1 is —(CH2)nN+HR3R4 X? or —(CH2)nNR3R4 when R2 is —N+HR6R7. R2 is —OR5, halogen, —NR6R7, —N+HR6R7 X?? sulphonic acid, nitro, —NR5COOR5, —NR5COR5 or —OCOR5; R3 and R4 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; each R5 is independently —H or a C1-C4 alkyl group; R6 and R7 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; n is an integer from 0-3; and X? is the carboxylate anion of an organic carboxylic acid compound. Also disclosed are methods of preparing certain compounds represented by Structural Formula (I).Type: GrantFiled: October 20, 2003Date of Patent: January 24, 2006Assignee: Xanthus Life Sciences, Inc.Inventors: Alfred M. Ajami, David O. Barlow
-
Patent number: 6987115Abstract: Compounds of the formula (I) are disclosed and are useful in the treatment bacterial infections: wherein: R1 is Ar or Het; R2 is C1-6alkyl, (R?)2N—(CH2)m— or Ar—C0-6alkyl; X is H, C1-4alkyl, OR?, SR?, C1-4alkylsulfonyl, C1-4alkylsulfoxyl, CN, N(R?)2, CH2N(R?)2, NO2, CF3, CO2R?, CON(R?)2, COR?, NR?C(O)R?, F, Cl, Br, I, or CF3S(O)r—; R? is H, C1-6alkyl or Ar—C0-6alkyl; each R? independently is H, C1-6alkyl or Ar—C0-6alkyl; m is 1 or 2; n is 0, 1 or 2; and r is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 7, 2001Date of Patent: January 17, 2006Assignee: SmithKline Beecham CorporationInventor: Mark A. Seefeld
-
Patent number: 6987116Abstract: This invention provides compounds of Formula (1a)-(1f) wherein: X, R1, and R2 are defined hereinbefore in the specification, which are useful in the treatment of cancer, stroke, osteoporosis, polycystic kidney disease, autoimmune disease, rheumatoid arthritis, and transplant rejection and process for producing said compounds.Type: GrantFiled: November 21, 2003Date of Patent: January 17, 2006Assignee: WyethInventors: Diane Harris Boschelli, Nan Zhang, Ana Carolina Barrios Sosa, Haris Durutlic, Biqi Wu
-
Patent number: 6987117Abstract: Compounds of the formula useful for the treatment of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse, and dysthymia.Type: GrantFiled: September 12, 2003Date of Patent: January 17, 2006Assignee: WyethInventors: Megan Tran, Gary P. Stack
-
Patent number: 6984646Abstract: The invention relates to imidazopyridinones of the formula wherein the groups R1, R2, R3, and R4 are as defined in claim 1, to the process for their preparation, to pharmaceutical compositions containing them, and to a method of using them for treatment of chronic inflammatory processes in humans or animals.Type: GrantFiled: July 15, 2002Date of Patent: January 10, 2006Assignee: Bayer Healhcare AGInventors: Cristina Alonso-Alija, Martin Michels, Hartmut Schirok, Karl-Heinz Schlemmer, Sara Dodd, Mary Fitzgerald, John Bell, Andrew Gill
-
Patent number: 6984635Abstract: Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.Type: GrantFiled: February 12, 1999Date of Patent: January 10, 2006Assignees: Board of Trustees of The Leland Stanford Jr. University, President and Fellows of Harvard CollegeInventors: Stuart L. Schreiber, Gerald R. Crabtree, Stephen D. Liberles
-
Patent number: 6982271Abstract: The present invention provides compounds, specifically novel tropane analogs, capable of acting as inhibitors of reuptake of monoamines. In preferred embodiments, these compositions are selective inhibitors of serotonin and/or norepinephrine reuptake. Also provided herein are pharmaceutical compositions comprising novel tropane analogs and a pharmaceutically acceptable carrier, and methods for treating conditions in which inhibition of reuptake of monoamines is desired. The inventive compositions as described herein are also useful for medical therapy and diagnosis.Type: GrantFiled: September 27, 2000Date of Patent: January 3, 2006Assignee: Georgetown UniversityInventors: Alan P. Kozikowski, Wolfgang Alexander Hoepping
-
Patent number: 6982334Abstract: The present invention comprises crystalline forms of 3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, represented by the structure: and as characterized herein by powder X-ray diffraction patterns as form A and form B, processes for preparing form A from the purified amorphous form of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, a processes for preparing form A by heating monohydrated form C of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, a pharmaceutical composition comprising form A, a pharmaceutical composition comprising form A and form B or monohydrated form C, a pharmaceutical composition comprising form A, form B and monohydrated form C, a method for treating a bacterial infection with form A, a method for treating a bacterial infection with form A and form B or monohydrated form C, and a method fType: GrantFiled: December 18, 2003Date of Patent: January 3, 2006Assignee: Aventis Pharma S.A.Inventors: Jacques Bourget, Marc Antoine Perrin, Serge Mignani, Bernd Janocha, Michel Cheve, Carole Neves, Pascal Billot, Michel Tabart, Sylvaine Lafont
-
Patent number: RE39128Abstract: The present invention relates to pleuromutilin derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medical therapy, particularly antibacterial therapy.Type: GrantFiled: October 27, 1998Date of Patent: June 13, 2006Assignee: SmithKline Beecham p.l.c.Inventors: Valerie Joan Berry, Steven Dabbs, Colin Henry Frydrych, Eric Hunt, Francis Dominic Sanderson, Gary Woodnutt